Description
Tirzepatide is a dual GIP/GLP-1 receptor agonist investigated for its role in metabolic research, body composition modulation, and glucose homeostasis. Unlike single-pathway agonists, tirzepatide’s dual mechanism engages both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing effects of significant interest to researchers studying energy regulation and metabolic signaling.
Each vial contains 10mg of lyophilized tirzepatide, produced to rigorous purity standards and supplied for in vitro and laboratory research purposes only.
We participate in a cooperative purchasing group in which members pool resources to conduct batch testing together, keeping verification costs manageable without compromising standards.
Orders are processed and shipped withing 48 hours.
Specification — Sequence: Dual GIP/GLP-1 Receptor Agonist — Appearance: White lyophilized powder — Molecular Weight: ~4,813 Da — Purity: ≥99% — Storage: −20°C long-term / 2–8°C short-term after reconstitution — Quantity: 10mg per vial
For research purposes only. Not for human use. Not for veterinary use. Must be handled by qualified personnel in a laboratory setting.
